Jorge E. Cortés

Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.

H. Kantarjian, J. Cortes, K. Yee, 2013, The Lancet. Oncology.

Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

G. Rosner, H. Kantarjian, G. Garcia-Manero, 2008, Blood.

Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.

J. Issa, H. Kantarjian, G. Garcia-Manero, 2010, Clinical Lymphoma, Myeloma & Leukemia.

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

T. Brümmendorf, M. Baccarani, H. Kantarjian, 2012, Blood.

Result of high-dose imatinib mesylate in patients with Philadelphia chromosome – positive chronic myeloid leukemia after failure of interferon -

H. Kantarjian, G. Garcia-Manero, J. Cortes, 2003 .

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.

R. Kurzrock, H. Kantarjian, G. Garcia-Manero, 2003, Blood.

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.

E. Estey, B. Cheson, S. Arbuck, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Pilot study of low-dose interleukin-11 in patients with bone marrow failure.

R. Kurzrock, J. Cortes, M. Talpaz, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.

H. Kantarjian, J. Cortes, S. Baker, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.